Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.

Slides:



Advertisements
Similar presentations
Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Eric D.
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Impact of Preoperative Renal Dysfunction in Patients Undergoing Off- pump vs On-pump Coronary Artery Bypass.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Jennifer Doria-del Castillo
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Impella Technology Elective Support Clinical Evidence and Investigations.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
Alexandre Quadros, Dulce Welter, Fernanda Camozzatto, Áurea Chaves, Rajendra Mehta, Carlos Gottschall, Renato D. Lopes Identifying Patients at Risk for.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Could an antianginal metabolic agent have an impact on prognosis in ischemic patients? Beneficial effects of trimetazidine in patients with acute myocardial.
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
Atorvastatin Versus Revascularization Treatments (AVERT) Trial Presented at The American Heart Association Scientific Sessions 1998 Presented by Dr. Bertram.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Risk Stratification in Unstable Angina Prospective Validation of the Braunwald Classification JAMA, January 11, 1995-Vol.273,No. 2.
Multivessel Coronary Artery Disease
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Interactions Between COPD and Outcomes After Percutaneous Coronary Intervention Tomas Konecny, Krishen Somers, Marek Orban, Yuki Koshino, Ryan J. Lennon,
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Procedural Outcomes of Chronic Total Occlusion Percutaneous.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prediction of 1-Year Mortality in Patients With Acute.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Total Occlusion Study of Canada (TOSCA-2) Trial
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
Complex Coronary intervention
Early Recovery of Left Ventricular Systolic Function After CoreValve Transcatheter Aortic Valve Replacement Harold L. Dauerman, MD; Michael J. Reardon,
Long-Term Forecasting and Comparison of Mortality in the Evaluation of the Xience Everolimus-Eluting Stent Versus Coronary Artery Bypass Surgery for Effectiveness.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.
First time a CETP inhibitor shows reduction of serious CV events
Circ Cardiovasc Interv
Circ Cardiovasc Interv
Giuseppe Biondi Zoccai, MD
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
No Financial Disclosure or Conflict of Interest
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Atlantic Cardiovascular Patient Outcomes Research Team
Glenn N. Levine et al. JACC 2011;58:e44-e122
Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Adjusted. ORs for outcomes by maintenance P2Y12 treatment
Presentation transcript:

Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention at the Philippine Heart Center Helenne Joie M. Brown, MD

Ischemic Heart Disease Risk Stratification Background Management Quality Control Evaluation of health economics

Objective Clinical Prognostic Value In-hospital and 30-day Mortality and MACCE New Mayo Clinic Risk Scores

Study Design Prospective Cohort Study Inclusion Criteria All patients who underwent percutaneous coronary intervention at the Philippine Heart Center during the period of April 1, 2011 to September 30, 2011, aged > 18 years were included. Exclusion Criteria Patients with no baseline systolic function.

Study Design Sample Size The computed sample size was > 460 based on 95% confidence level and 80% power to detect statistical significance at assumed difference in area under the curve of 10%. The assumption was based on the paper of Garg et al which presented an AUC of 0.89 for MACE. Garg S et al. A New Tool for the Risk Stratification of Patients with Complex Coronary Artery Disease: The Clinical SYNTAX Score. Circ Cardiovasc Interv. 2010;3:

Study Design Study Maneuver Ischemic Heart Disease PCI Cardiovascular history and risk factors Coronary Angiogram 2 Interventional Cardiologists

Clinical New Mayo Clinic Risk Scores Study Design Study Maneuver Age Serum creatinine LVEF Preprocedural shock = 9 points MI < 24 hours = 4 points CHF on presentation = 3 points PAD = 2 points CSS = [SYNTAX Score] x [modified ACEF score]

Clinical New Mayo Clinic Risk Scores Study Design Study Maneuver Age Serum creatinine LVEF Preprocedural shock MI < 24 hours CHF on presentation PAD CSS = [SYNTAX Score] x [modified ACEF score]

Clinical New Mayo Clinic Risk Scores Study Design Study Maneuver Risk Stratification Low-risk: < 15.6 Moderate risk: >15.6 <27.5 High risk: >27.5 Mortality Prediction Very low risk: 0-5 Low-risk: 6-7 Moderate risk: 8-10 High risk: Very high risk: 13+ MACCE Prediction Very low risk: 0-2 Low-risk: 3-5 Moderate risk: 6-90 High risk: Very high risk: 14+ Outcomes In-hospital and 30-day all-cause mortality and MACCE

Clinical New Mayo Clinic Risk Scores Study Maneuver Risk Stratification Low-risk: < 15.6 Moderate risk: >15.6 <27.5 High risk: >27.5 Mortality Prediction Very low risk: 0-5 Low-risk: 6-7 Moderate risk: 8-10 High risk: Very high risk: 13+ MACCE Prediction Very low risk: 0-2 Low-risk: 3-5 Moderate risk: 6-90 High risk: Very high risk: 14+ Outcomes In-hospital and 30-day all-cause mortality and MACCE Results N = 482

Variable n = 482 MeanSD Age, + SD, years Serum Creatinine, mg/dl Creatinine Clearance, ml/min LVEF, % Table 1. Baseline and Procedural Variables Results

Variable n= 482 No.% Gender Male Female Myocardial Infarction < 24 hours Unstable Angina Non-elective PCI Diabetes mellitus Current and previous smoker Hypertension Dyslipidemia CHF on presentation Table 1. Baseline and Procedural Variables Results

Variable n= 482 No.% NYHA Class III or IV224.6 PAD234.8 Previous PCI408.3 Previous CABG296.0 Previous MI Previous CVA204.1 Family History of IHD Table 1. Baseline and Procedural Variables Results

Variable n= 482 No.% Meds at Screening ASA Clopidogrel B-blockers ACE inhibitors/ARBs Statins Table 1. Baseline and Procedural Variables Results

Clinical New Mayo Clinic Risk Scores Risk Stratification Low-risk: < 15.6 Moderate risk: >15.6 <27.5 High risk: >27.5 Mortality Prediction Very low risk: 0-5 Low-risk: 6-7 Moderate risk: 8-10 High risk: Very high risk: 13+ MACCE Prediction Very low risk: 0-2 Low-risk: 3-5 Moderate risk: 6-90 High risk: Very high risk: 14+ Outcomes In-hospital and 30-day all-cause mortality and MACCE Results N = 482

Event n= 482 No.% Mortality224.6 Myocardial Infarction51 Emergency CABG10.2 CVA91.9 Table 2. In-hospital Mortality and MACCE following PCI Results

Figure 1. ROC Curve for In-hospital Mortality for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

Figure 6. ROC Curve for In-hospital Composite Endpoints for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

Clinical New Mayo Clinic Risk Scores Risk Stratification Low-risk: < 15.6 Moderate risk: >15.6 <27.5 High risk: >27.5 Mortality Prediction Very low risk: 0-5 Low-risk: 6-7 Moderate risk: 8-10 High risk: Very high risk: 13+ MACCE Prediction Very low risk: 0-2 Low-risk: 3-5 Moderate risk: 6-90 High risk: Very high risk: 14+ Outcomes In-hospital and 30-day all-cause mortality and MACCE Results N = 482

Event n= 482 No.% Mortality92 Myocardial Infarction92 Emergency CABG00 CVA10.2 Table day Mortality and MACCE following PCI Results

Figure 2. ROC Curve for In-hospital Myocardial Infarction for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

Figure 3. ROC Curve for In-hospital CVA for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

Figure 4. ROC Curve for 30-day Mortality for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

Figure 7. ROC Curve for 30-day Composite Endpoints for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

Figure 8. ROC Curve for In-hospital and 30-day Composite Endpoints for the New Mayo Clinic Risk Score (NMCRS) for Predicting Mortality, the NMCRS for Predicting MACE and the Clinical Syntax Score (CSS).

versus Age Serum creatinine LVEF Garg et al. A New Tool for the Risk Stratification of Patients with Complex Coronary Artery Disease: The Clinical SYNTAX Score. Circ Cardiovasc Interv. 2010;3:  predictors of adverse outcomes after revascularization Ranucci et al. Risk of Assessing Mortality Risk in Elective Cardiac Operations: Age, Creatinine, Ejection Fraction, and the Law of Parsimony. Circulation. 2009;119:  not subject to interobserver variability

Risk Stratification Mortality PredictionMACCE Prediction Outcomes In-hospital and 30-day all-cause mortality and MACCE Results Clinical variables Clinical + angiographic variables

versus “… despite exclusion of angiographic variables, the NMCRS can accurately estimate peri-procedural risk from PCI.” Singh et al. Bedside Estimation of Risk from Percutaneous Coronary Intervention: The New Mayo Clinic Risk Scores. Mayo Clin Proc June 2007;82(6): Our study demonstrated that the prognostic utility of the NMCRS for predicting mortality and MACCE can be extended to estimation of mortality and MACCE 30 days after a patient undergoes PCI.

versus all-comers study: 1-, 2- 3-vessel CAD 2- or 3-vessel CAD Excluded: Previous PTCA Left Main CAD Overt CHF LVEF < 30% Hx of TIA Hx of transmural MI Utility: long-term outcomes

Conclusion This study demonstrates the superior ability of a risk stratification tool which uses purely clinical variables, i.e. (1) the NMCRS for Predicting Mortality to predict in-hospital mortality and composite MACCE and (2) the NMCRS for Predicting MACE to predict 30-day mortality and composite MACCE, when compared with the CSS which uses angiographic and clinical variables.

Recommendation We therefore recommend the use of the New Mayo Clinic Risk Score for risk stratification of patients who will undergo PCI.  simple bedside tool  expedient for both the physician and patient in decision-making for revascularization  superior discriminative ability over the Clinical Syntax Score for peri-procedural and 30-day adverse outcomes

Good afternoon.